Crinetics Pharmaceuticals (CRNX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed attendees and outlined the virtual format and participation guidelines.
The agenda included three main proposals: election of directors, ratification of the auditor, and an advisory vote on executive compensation.
Board and executive committee updates
Three nominees for Class two directors were presented for election to serve until the 2029 annual meeting.
Shareholder proposals
Stockholders were asked to vote on the election of directors, ratification of the independent auditor, and approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Crinetics Pharmaceuticals
- Q3 net loss rose to $76.8M; $1.4B cash funds pipeline and 2025 launch plans.CRNX
Q3 20244 Jun 2026 - Q2 2024 saw strong cash reserves, positive clinical data, and NDA plans for paltusotine.CRNX
Q2 20244 Jun 2026 - $1.4B cash runway, NDA acceptance, and late-stage pipeline set stage for 2025 growth.CRNX
Q4 20244 Jun 2026 - Q1 2025 net loss widened, but $1.3B cash supports pipeline, launch, and global expansion.CRNX
Q1 20254 Jun 2026 - Net loss reached $115.6M in Q2 2025 as paltusotine neared FDA approval and cash reserves stayed strong.CRNX
Q2 20254 Jun 2026 - PALSONIFY's launch fueled Q1 revenue growth, global expansion, and robust liquidity despite higher losses.CRNX
Q1 202611 May 2026 - Annual meeting to elect directors, ratify PwC, and approve executive pay, with strong governance focus.CRNX
Proxy filing29 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.CRNX
Proxy filing29 Apr 2026 - PALSONIFY launch drives strong early uptake, net loss widens, cash runway extends into 2029.CRNX
Q3 202516 Apr 2026